ES-REFLUJO: Protocol for the ESREFLUJO Study: Epidemiological Study of Heartburn and Gastroesophageal Reflux in Community Pharmacy

Sponsor
Universidad Miguel Hernandez de Elche (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05162079
Collaborator
(none)
1,200
6

Study Details

Study Description

Brief Summary

Introduction: Symptoms as heartburn and/or reflux is frequent consultations in community pharmacies, the characterization of them is crucial to provide appropriate patient counseling. To facilitate the assistance work of the community pharmacist and its coordination between different levels of care, a group of experts in Community Pharmacy, Primary Care, and Gastroenterology has recently worked on an algorithm to manage these symptoms.

Objective: Analyse the epidemiological characteristics of patients who consult for symptoms of heartburn and/or reflux in Spanish community pharmacies, and evaluate the clinical and humanistic results of the protocolization of a Professional Pharmaceutical Service in said patients.

Methods and analysis: The study design consists of a cross-sectional descriptive part, in which the clinical and sociodemographic characteristics of the patients who come to the community pharmacy will be evaluated for consultation derived from heartburn and/or reflux symptoms and a before-after descriptive study in which will evaluate the clinical and humanistic results in patients who come to the pharmacy after receiving pharmaceutical care.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Protocol for the ESREFLUJO Study: Epidemiological Study of Heartburn and Gastroesophageal Reflux in Community Pharmacy
    Anticipated Study Start Date :
    Mar 1, 2022
    Anticipated Primary Completion Date :
    Jul 1, 2022
    Anticipated Study Completion Date :
    Sep 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Collection of sociodemographic data of participants [8 minutes each questionnaire]

      At the initial visit, sociodemographic variables will be collected through a Data Collection Notebook (CDR): sex, age, level of education, employment status, civil status.

    2. Collection of clinical data of participants [8 minutes each questionnaire]

      At the initial visit, clinical data will be collected through a Data Collection Notebook (CDR): Risk factors: Body mass index (BMI), smoking, food consumption • Weight and height will be combined to report BMI in kg/m^2. Symptoms throught the questionnaire: The Gastro-oesophageal Reflux Disease Impact Scale (GIS) Treatments or medications used

    3. Detail the evolution of the patient's symptoms 14 days after intervention [5 minutes]

      An independent external monitor will make a telephone call to each patient to collect the evolution of the patient´s symptoms through a questionnaire: The Gastro-oesophageal Reflux Disease Impact Scale (GIS). It is a scale of frequency, the lower scores mean better health in the patient less frequency of disturbances)

    4. Evaluate patient satisfaction [5 minutes]

      An independent external monitor will make a telephone call to each patient to collect the evolution of the patient´s symptoms through a questionnaire: Degree of satisfaction with the pharmaceutical care received (The score is the level of agreement, high punctuation means more satisfaction) and If the patient gets medication: Treatment Satisfaction Questionnaire for Medication (TSMQ, v1.4). (The score is the level of satisfaction, high punctuation means more satisfaction)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Population´s age ≥ 18 years

    • Patients who consult for mild symptoms of heartburn and/or gastroesophageal reflux or request treatment for it.

    Exclusion Criteria:
    • Subjects who request treatment for symptoms of heartburn and/or gastroesophageal reflux for another person

    • Women with high-risk pregnancies

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Universidad Miguel Hernandez de Elche

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Elsa López Pintor, Lecturer, Universidad Miguel Hernandez de Elche
    ClinicalTrials.gov Identifier:
    NCT05162079
    Other Study ID Numbers:
    • SEFAC1.20I.
    First Posted:
    Dec 17, 2021
    Last Update Posted:
    Dec 17, 2021
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Elsa López Pintor, Lecturer, Universidad Miguel Hernandez de Elche
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 17, 2021